{
  "pmcid": "10481925",
  "sha256": "c546241342dd65f1569454e83a12873a34256945a7d7755e87fade1788c3d870",
  "timestamp_utc": "2025-11-09T15:09:08.515066+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.322841719683826,
    "reading_ease": 39.475228455754774,
    "word_count": 273
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Objective:: The aim of the present randomized controlled trial was to evaluate the superiority of indocyanine green fluorescence imaging (ICG-FI) in reducing the rate of anastomotic leakage in minimally invasive rectal cancer surgery."
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This randomized, open-label, phase 3, trial was performed at 41 hospitals in Japan."
      },
      "Participants": {
        "score": 2,
        "evidence": "Patients with clinically stage 0–III rectal carcinoma less than 12 cm from the anal verge, scheduled for minimally invasive sphincter-preserving surgery were preoperatively randomly assigned."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Patients were preoperatively randomly assigned to receive a blood flow evaluation by ICG-FI (ICG+ group) or no blood flow evaluation by ICG-FI (ICG− group)."
      },
      "Objective": {
        "score": 1,
        "evidence": "Objective:: The aim of the present randomized controlled trial was to evaluate the superiority of indocyanine green fluorescence imaging (ICG-FI) in reducing the rate of anastomotic leakage in minimally invasive rectal cancer surgery."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary endpoint was the anastomotic leakage rate (grade A+B+C, expected reduction rate of 6%) analyzed in the modified intention-to-treat population."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Patients were preoperatively randomly assigned."
      },
      "Blinding": {
        "score": 3,
        "evidence": "This randomized, open-label, phase 3, trial was performed at 41 hospitals in Japan."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Between December 2018 and February 2021, a total of 850 patients were enrolled and randomized."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "After the exclusion of 11 patients, 839 were subject to the modified intention-to-treat population (422 in the ICG+ group and 417 in the ICG− group)."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The rate of anastomotic leakage (grade A+B+C) was significantly lower in the ICG+ group (7.6%) than in the ICG− group (11.8%) (relative risk, 0.645; 95% confidence interval 0.422–0.987; P =0.041)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 21,
    "max_score": 25
  }
}